. J Clin Oncol 1996 ; 14 : 2631 – 2637 . 8 Margolin KA Doroshow JH Frankel P . Taxol-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer . (Submitted for publication) . 9 Broun ER
Search Results
Management of Advanced Germ Cell Cancer in Patients With Unfavorable Prognosis
Kim Margolin
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes
decreased in older patients treated with PCI compared with younger patients regardless of stage. 149 Surveillance for Relapse Although SCLC is very responsive to initial treatment, most patients relapse with relatively resistant disease (see also
Use of PARP Inhibitors for Ovarian Cancer
Presented by: Deborah K. Armstrong
there is no information on whether these benefits would be seen in patients who had previously received PARP inhibitors. Recurrent Disease Active treatment of relapsed disease with PARP inhibitors has also been well tested in BRCA -positive
Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
cancer. BMC Cancer 2006;6:194; and Elkum N, Dermime S, Ajarim D, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007;7:222. Based on international
Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme
Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick
locally, with 90% of relapses occurring within 2 cm of the original tumor. 4 As reflected in the NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, therapies are variable and depend on the extent of recurrence and the
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar
criteria for a CR or PR are considered to have stable disease. Relapse is defined as evidence of disease progression 6 months or more after an initial CR or PR. Refractory disease is defined as failure to experience a response or experiencing disease
A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer
Kazuki Sudo, Xuemei Wang, Lianchun Xiao, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, David C. Rice, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Adarsh Hiremath, Nikolaos Charalampakis, Ritsuko Komaki, Mariela A. Blum, Stephen G. Swisher, Dipen M. Maru, Heath D. Skinner, Jeana L. Garris, Jane E. Rogers, Wayne L. Hofstetter, and Jaffer A. Ajani
Background Among patients with localized esophageal cancer (LEC), 35% or more develop distant metastases (DM) as first relapse, most in the first 24 months after local therapy. 1 Worldwide, yearly new cases of esophageal cancer are estimated
Postconsolidation Maintenance and Monitoring in Patients With Acute Promyelocytic Leukemia
Chezi Ganzel, Dan Douer, and Martin S. Tallman
Era ATO is considered the most potent anti-APL agent. Its use, which was traditionally reserved for patients experiencing relapse, has expanded and become more a part of induction-consolidation therapy. 15 , 16 Recently, primary results of the APL
Management of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia
Samuel J. Slomowitz and Paul J. Shami
, chloroma , or myeloblastoma ), leukemia cutis (LC), and central nervous system (CNS) disease. Extramedullary disease at presentation or relapse can pose unique clinical problems. In general, the basic principles of systemic therapy remain the same. The
Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines
Justine M. Kahn and Melissa Beauchemin
– 3 Hodgkin lymphoma (HL) represents an ideal paradigm for understanding cancer disparities, because successful treatments are well established in both the up-front and relapse treatment settings. Today, 5-year overall survival (OS) rates for children
